Capitalizing on ADC frenzy, ProfoundBio attracts $112M oversubscribed series B jwaldron Mon, 02/12/2024 - 10:55.: With Big Pharmas heading into 2024 with a renewed interest in antibody-drug conjugates (ADCs), it’s no surprise that ProfoundBio managed to assemble a who’s who of biotech investors for an oversubscribed series B round. The likes of Lilly Asia Ventures, RA Capital Management, OrbiMed, Medicxi and LifeSci Venture Partners all featured in the $112 million round, which was led by Ally Bridge Group.